$142.0M
1 filing since 2024 · latest Equity filed
NGM Bio Holdings is the parent company of NGM Biopharmaceuticals, a privately held clinical-stage biotechnology company in South San Francisco that discovers and develops antibody and protein therapeutics from its own biology-led discovery engine. Its lead candidate NGM120 is a GFRAL antagonist antibody that blocks GDF15 signaling, in Phase 2 development for hyperemesis gravidarum (the EMERALD study) and for cancer cachexia. A second program, aldafermin, is an engineered analog of the human hormone FGF19 in development for primary sclerosing cholangitis. The company was taken private from Nasdaq by longtime investor The Column Group in April 2024 and refinanced with a Series A the following July.
What sets it apart
A biology-first discovery engine that generated every candidate in its pipeline in house, now concentrated on the GDF15/GFRAL axis - a mechanism with no approved therapy - in indications such as hyperemesis gravidarum and cancer cachexia where current care is largely supportive.
An investigational monoclonal antibody antagonist of GFRAL, the receptor for GDF15, designed to block GDF15 signaling in brainstem cells that trigger nausea, vomiting and appetite suppression.
